Exelixis Inc. (EXEL) Given Consensus Rating of “Buy” by Brokerages
Exelixis Inc. (NASDAQ:EXEL) has received a consensus rating of “Buy” from the eight analysts that are covering the stock. Seven analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have issued a report on the stock in the last year is $15.31.
A number of analysts have commented on the stock. Leerink Swann reaffirmed an “outperform” rating and set a $12.00 target price on shares of Exelixis in a report on Thursday, August 18th. Stifel Nicolaus lifted their target price on shares of Exelixis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, August 4th. Cowen and Company reaffirmed a “buy” rating on shares of Exelixis in a report on Wednesday, August 10th. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a report on Tuesday, September 13th. Finally, Piper Jaffray Cos. reaffirmed a “neutral” rating and set a $8.00 target price (up previously from $5.00) on shares of Exelixis in a report on Thursday, August 4th.
Shares of Exelixis (NASDAQ:EXEL) traded up 1.23% during midday trading on Thursday, reaching $16.83. 3,320,250 shares of the company’s stock traded hands. The stock has a 50 day moving average of $12.59 and a 200-day moving average of $9.88. Exelixis has a 12 month low of $3.55 and a 12 month high of $17.00. The stock’s market cap is $4821.05 billion.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Thursday, November 3rd. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.09. The company earned $62.19 million during the quarter, compared to the consensus estimate of $43.15 million. During the same quarter last year, the firm earned ($0.22) EPS. The business’s revenue for the quarter was up 531.1% on a year-over-year basis. On average, equities research analysts forecast that Exelixis will post ($0.47) EPS for the current fiscal year.
Several institutional investors have recently made changes to their positions in the stock. Baker BROS. Advisors LP bought a new position in shares of Exelixis during the third quarter worth $63,048,000. Farallon Capital Management LLC bought a new position in shares of Exelixis during the second quarter worth $38,386,000. Janus Capital Management LLC bought a new position in shares of Exelixis during the second quarter worth $25,702,000. Lord Abbett & CO. LLC bought a new position in shares of Exelixis during the second quarter worth $22,690,000. Finally, Acadian Asset Management LLC bought a new position in shares of Exelixis during the third quarter worth $28,867,000. 84.45% of the stock is owned by institutional investors.
Exelixis, Inc is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.
Receive News & Stock Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related stocks with our FREE daily email newsletter.